Evaluation of the efficacy of Mavaceta/Mefanto in the treatment of cardiac hypertrophy

Hypertrophic cardiomyopathy (HCM) is a common hereditary heart disease in which the patient's heart muscle overproliferates due to various reasons (usually genetic mutations), resulting in severe impact on heart function. HCM patients often experience symptoms such as dyspnea, chest pain, syncope, and even cardiac arrest. In the past, treatment options for such patients were relatively limited, relying mainly on medications such as beta-blockers and calcium channel blockers, or surgical treatments such as heart transplantation or myectomy. However, these traditional treatments do not effectively address the root causes of the disease and are often accompanied by side effects.

Mavacamten (mavacamten) is a new treatment method that inhibits excessive myocardial contraction by targeting the interaction between actin and myosin in cardiac muscle cells, thereby alleviating the symptoms of cardiac hypertrophy. Clinical trial results show that Mavacamten can effectively reduce left ventricular hypertrophy, improve heart function, and reduce related symptoms such as dyspnea and chest pain in patients with hypertrophic cardiomyopathy. Additionally, it significantly reduces patients' dependence on other medications, such as beta-blockers.

According to the results of multiple large-scale clinical trials such as EXPLORER-HCM and MAVA-LTE, Mavakate has been proven to significantly improve the quality of life of HCM patients and improve their exercise ability. Especially in patients with severe left ventricular outflow tract obstruction, the effect of Mavaceta is particularly outstanding. In these patients, Mavacartide was able to effectively reduce obstruction, reduce disease-related risks, and improve patients' exercise tolerance.

Through systematic evaluation of the heart function ofHCM patients, researchers found that after treatment with Mavaceta, the patients' cardiac ejection fraction was improved, and there were significant changes in heart size and myocardial thickness. This series of therapeutic effects proves the potential of Mavaceta in the treatment of hypertrophic cardiomyopathy, especially its role in improving the structure and function of the patient's heart.

Reference materials:https://bnf.nice.org.uk/drugs/mavacamten/